BRPI1010647A2 - combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um composto antidiabético para uso no tratamento de doenças proliferativas - Google Patents

combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um composto antidiabético para uso no tratamento de doenças proliferativas

Info

Publication number
BRPI1010647A2
BRPI1010647A2 BRPI1010647A BRPI1010647A BRPI1010647A2 BR PI1010647 A2 BRPI1010647 A2 BR PI1010647A2 BR PI1010647 A BRPI1010647 A BR PI1010647A BR PI1010647 A BRPI1010647 A BR PI1010647A BR PI1010647 A2 BRPI1010647 A2 BR PI1010647A2
Authority
BR
Brazil
Prior art keywords
phosphoinositide
treatment
combination
kinase inhibitor
proliferative diseases
Prior art date
Application number
BRPI1010647A
Other languages
English (en)
Inventor
Bing Wang
Jeroen Antonius Johannes Schmitt
Magali Faure
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BRPI1010647A2 publication Critical patent/BRPI1010647A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pediatric Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BRPI1010647A 2009-05-12 2010-05-07 combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um composto antidiabético para uso no tratamento de doenças proliferativas BRPI1010647A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159964A EP2251029A1 (en) 2009-05-12 2009-05-12 Lactoferrin and gut neuronal health in adults and/or elderly
PCT/EP2010/056238 WO2010130644A1 (en) 2009-05-12 2010-05-07 Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
BRPI1010647A2 true BRPI1010647A2 (pt) 2016-03-15

Family

ID=41110391

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010647A BRPI1010647A2 (pt) 2009-05-12 2010-05-07 combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um composto antidiabético para uso no tratamento de doenças proliferativas

Country Status (6)

Country Link
US (2) US8592369B2 (pt)
EP (2) EP2251029A1 (pt)
JP (2) JP2012526747A (pt)
CN (1) CN102458449B (pt)
BR (1) BRPI1010647A2 (pt)
WO (1) WO2010130644A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2251031A1 (en) * 2009-05-12 2010-11-17 Nestec S.A. Lactoferrin and neuronal health and development in the infant gut
PL2594282T3 (pl) * 2011-11-21 2015-01-30 Nestec Sa Laktoferyna i istota biała
MX2016001225A (es) * 2013-09-02 2016-05-24 Nestec Sa Lactoferrina y memoria y velocidad de aprendizaje en niños.
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
CN110839698A (zh) * 2019-11-29 2020-02-28 内蒙古伊利实业集团股份有限公司 一种组合物及其食品用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
ATE84680T1 (de) 1987-12-23 1993-02-15 Nestle Sa Verfahren zur herstellung eines molkeeiweisshydrolysates und eines hypoallergenen nahrungsmittels.
JPH0779684B2 (ja) * 1989-02-27 1995-08-30 森永乳業株式会社 ビフィズス菌増殖促進組成物
JP2660908B2 (ja) * 1995-02-24 1997-10-08 森永乳業株式会社 ビフィズス菌増殖促進性及び生残性が良好なヨーグルト
EP0880902A1 (fr) 1997-05-27 1998-12-02 Nestlé Produkte AG Procédé de traitement d'une matiére première lactosérique
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
CA2371696C (en) 1999-04-29 2005-11-15 Societe Des Produits Nestle S.A. Composition for an infant formula having a low threonine content
JP4452569B2 (ja) * 2004-06-29 2010-04-21 有限会社フードデザイン健康研究所 桃の花及びラクトフェリンを主成分とする食品
US20060068022A1 (en) * 2004-09-29 2006-03-30 Playford Raymond J Bioactive agent compositions for repair of cell injuries
US20070036873A1 (en) * 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CN101472612B (zh) * 2006-06-14 2011-06-08 纽崔西亚公司 包含甘氨酸和乳铁蛋白的抗炎组合物及其应用
ITRM20060434A1 (it) * 2006-08-07 2008-02-08 Pietro Raimondi Prodotto da somministrare all organismo umano per isuoi effetti protettivi e curativi a base di latte di bufala autorricchito di lattoferrina oppure di lattoferrina tal quale ottenuto attraverso processi separativi di membrana

Also Published As

Publication number Publication date
CN102458449B (zh) 2015-04-08
US9095570B2 (en) 2015-08-04
WO2010130644A8 (en) 2011-12-22
JP2012526747A (ja) 2012-11-01
US20140135262A1 (en) 2014-05-15
WO2010130644A1 (en) 2010-11-18
US8592369B2 (en) 2013-11-26
EP2429570A1 (en) 2012-03-21
JP2016020357A (ja) 2016-02-04
EP2251029A1 (en) 2010-11-17
CN102458449A (zh) 2012-05-16
US20120270777A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
BRPI0816769A2 (pt) combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
BRPI0906831A2 (pt) uso de um inibidor de gama-secretase para tratamento de câncer
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI1008498A2 (pt) Composto, prodroga do composto, medicamento, e, uso de um composto.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BRPI0914069A2 (pt) composição de vacina para uso contra o influenza
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0906352A2 (pt) Derivado de tiazol e uso do mesmo como inibidores de vap-1
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0808813A2 (pt) método para a preparação de compostos de borracha, e, uso de compostos
ITMI20080003A1 (it) Composizioni per uso oftalmico
BRPI0915336A2 (pt) composto capaz de inibir a atividade de uma pad, composição, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/40 (2006.01), A23L 2/66 (2006.0

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.